Latest Manor Royal Press Releases
Manor Royal-based Varian awarded contract worth up to £80m
Varian Medical Systems, the world leader in radiotherapy systems and software, has been selected to equip and service two new national proton therapy centres in England in a contract valued at up to £80 million.
"Varian is proud to have been selected as the preferred equipment supplier for these new proton therapy facilities," said Dow Wilson, Varian's chief executive officer. "As the leading supplier of radiotherapy equipment and software to the National Health Service, we will be able to leverage our existing UK-based engineering and logistics infrastructure to deliver industry leading technology while meeting the NHS requirements for value for money. This major project will result in a number of additional highly-skilled engineering jobs and an expansion of our UK organization, which currently includes both manufacturing and support."
Under a public tender, Varian was selected as the preferred supplier to provide equipment and service to operate two three-room centres to be constructed at UCLH (University College London Hospitals NHS Foundation Trust) in London and The Christie NHS Foundation Trust in Manchester. Equipment installation is expected to take place from August 2017, with patient treatments expected to begin from 2018.
Proton therapy makes it possible to treat certain types of cancer more precisely and with potentially fewer side effects than is possible with conventional radiation therapy. With proton therapy, the risk of damage to healthy tissues and potential side effects is reduced because the beam stops and deposits dose within the tumor site rather than passing all the way through the patient. In pediatric patients the risk of developing a new, radiation-induced cancer later in life may be reduced.
Varian's ProBeamTM system with Dynamic PeakTM Scanning is uniquely capable of high-speed intensity modulated proton therapy (IMPT) which is the most precise form of proton therapy available. ProBeam technology is being used to treat patients at the Scripps Proton Therapy Center in San Diego, the Rinecker Proton Therapy Center in Munich, and the Paul Scherrer Institute in Switzerland. Varian also has contracts for system installations at eight other sites around the world.